We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology

News   Nov 19, 2010

 
Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology
 
 
 

RELATED ARTICLES

Chemists’ Success in Synthesis Drives Development of Anti-cancer Agent

News

Researchers have now synthesized sufficient quantities of E7130, a drug candidate from the halichondrin class, to enable for the first time rigorous studies of its biological activity, pharmacological properties, and efficacy.

READ MORE

Shoulder Pain Relief for Wheelchair Users With Spinal Cord Injury

News

Researchers report initial results for a minimally invasive intervention for relief of chronic refractory shoulder pain in upper-limb dependent individuals with spinal cord injury.

READ MORE

Epilepsy Drugs Linked to Increased Risk of Suicidal Behavior, Study Finds

News

Treatment with a group of drugs used for epilepsy, nerve pain and anxiety disorders – called gabapentinoids – is associated with an increased risk of suicidal behavior, unintentional overdose, injuries, and road traffic incidents, according to a new study published in BMJ.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE